Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine–DNA Methyltransferase Biomarker Analyses
Journal of Clinical Oncology - United States
doi 10.1200/jco.2015.64.7685
Full Text
Open PDFAbstract
Available in full text
Date
January 20, 2017
Authors
Publisher
American Society of Clinical Oncology (ASCO)